ibutilide has been researched along with sotalol in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (38.46) | 18.2507 |
| 2000's | 14 (53.85) | 29.6817 |
| 2010's | 2 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brunden, MN; Buchanan, LV; Gibson, JK; Kabell, G; Turcotte, UM | 1 |
| Brunden, MN; Buchanan, LV; Gibson, JK; Kabell, G | 1 |
| Baskin, EP; Guinosso, PJ; Hamill, T; Lynch, JJ; Nutt, EM; Salata, JJ; Woods, CM | 1 |
| Lee, EW; Lee, KS; Tsai, TD | 1 |
| Brunden, MN; Buchanan, LV; Gibson, JK; Hsu, CY; LeMay, RJ; Walters, RR | 1 |
| DiMarco, JP; Jung, F | 1 |
| Bharucha, D; Kowey, PR; Marinchak, RA; Rials, SJ | 1 |
| Golitsyn, SR; Harry, JD; Perry, KT; Ruda, MY; Stangl, K; Steinbeck, G; Touboul, P; Van Wijk, LV; Vos, MA; Wellens, HJ | 1 |
| Podrid, PJ | 1 |
| Sager, PT | 1 |
| Dorian, P; Qi, X | 1 |
| Bianconi, L; Castro, A; Santini, M | 1 |
| Brendel, J; Busch, AE; Knobloch, K; Peukert, S; Rosenstein, B; Wirth, KJ | 1 |
| DeBisschop, M; Lower, DL; Martin, LG; Yamreudeewong, W | 1 |
| Khan, MH | 1 |
| Bleich, M; Brendel, J; Busch, AE; Knobloch, K; Rosenstein, B; Wirth, KJ | 1 |
| Borchard, R; Brandts, B; Dirkmann, D; Meine, M; Prull, MW; Trappe, HJ; Van Bracht, M; Wickenbrock, I | 1 |
| Brendorp, B; Elming, H; Køber, L; Pedersen, OD; Pehrson, S; Torp-Petersen, C | 1 |
| Allessie, M; Blaauw, Y; Duytschaever, M | 1 |
| Scharf, C | 1 |
| Kluger, J; Shah, SA; White, CM | 1 |
11 review(s) available for ibutilide and sotalol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Antiarrhythmic drug therapy in the treatment of atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Electrophysiology; Flecainide; Humans; Ion Channels; Quinidine; Sotalol; Sulfonamides | 1996 |
Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Compounds; Humans; Phenethylamines; Sotalol; Sulfonamides | 1997 |
New advances in class III antiarrhythmic drug therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiology; Humans; Hydantoins; Imidazoles; Imidazolidines; Phenethylamines; Piperazines; Sotalol; Sulfonamides | 2000 |
Antiarrhythmic drugs and ventricular defibrillation energy requirements.
Topics: Animals; Anti-Arrhythmia Agents; Defibrillators, Implantable; Humans; Phenethylamines; Sotalol; Sulfonamides; Ventricular Fibrillation | 1999 |
New antiarrhythmic drugs for the treatment of atrial fibrillation.
Topics: Aminobenzoates; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Cyclopropanes; Dronedarone; Humans; Hydantoins; Imidazoles; Imidazolidines; Phenethylamines; Piperazines; Sotalol; Sulfonamides | 2002 |
Potentially significant drug interactions of class III antiarrhythmic drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Compounds; Drug Interactions; Humans; Phenethylamines; Sotalol; Sulfonamides | 2003 |
Oral class III antiarrhythmics: what is new?
Topics: Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Humans; Hydantoins; Imidazoles; Imidazolidines; Phenethylamines; Piperazines; Sotalol; Sulfonamides; Tachycardia, Supraventricular; Tachycardia, Ventricular; Treatment Outcome | 2004 |
A benefit-risk assessment of class III antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Combined Modality Therapy; Defibrillators, Implantable; Dronedarone; Heart Conduction System; Humans; Hydantoins; Imidazolidines; Ion Transport; Life Tables; Membrane Potentials; Meta-Analysis as Topic; Phenethylamines; Piperazines; Risk Assessment; Sotalol; Sulfonamides; Survival Analysis; Torsades de Pointes; Treatment Outcome | 2004 |
[Atrial flutter and fibrillation].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Calcium Channel Blockers; Catheter Ablation; Clinical Trials as Topic; Disopyramide; Electric Countershock; Electrocardiography; Emergencies; Flecainide; Heart Rate; Humans; Middle Aged; Pacemaker, Artificial; Propafenone; Quinidine; Recurrence; Sotalol; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2005 |
Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Drug Therapy, Combination; Electrocardiography; Electrophysiologic Techniques, Cardiac; Heart Conduction System; Humans; Sotalol; Sulfonamides; Torsades de Pointes | 2007 |
1 trial(s) available for ibutilide and sotalol
| Article | Year |
|---|---|
Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Sotalol; Sulfonamides; Time Factors | 1998 |
14 other study(ies) available for ibutilide and sotalol
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Electrocardiography; Encainide; Hemodynamics; Myocardial Infarction; Sotalol; Sulfonamides | 1992 |
Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia.
Topics: Animals; Anti-Arrhythmia Agents; Blood Pressure; Electrocardiography; Heart Conduction System; Heart Rate; Male; Methoxamine; Phenethylamines; Piperidines; Pyridines; Quaternary Ammonium Compounds; Rabbits; Software; Sotalol; Sulfonamides; Torsades de Pointes | 1993 |
Comparison of binding to rapidly activating delayed rectifier K+ channel, IKr, and effects on myocardial refractoriness for class III antiarrhythmic agents.
Topics: Animals; Anti-Arrhythmia Agents; Binding, Competitive; Chromans; Electrophysiology; Guinea Pigs; Heart Ventricles; Papillary Muscles; Phenethylamines; Piperidines; Potassium Channel Blockers; Potassium Channels; Procainamide; Pyridines; Sotalol; Structure-Activity Relationship; Sulfonamides; Tritium | 1995 |
Membrane activity of class III antiarrhythmic compounds; a comparison between ibutilide, d-sotalol, E-4031, sematilide and dofetilide.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Guinea Pigs; Heart; In Vitro Techniques; Membrane Potentials; Phenethylamines; Piperidines; Potassium Channels; Procainamide; Pyridines; Sotalol; Sulfonamides | 1993 |
Antiarrhythmic and electrophysiologic effects of intravenous ibutilide and sotalol in the canine sterile pericarditis model.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Flutter; Cross-Over Studies; Dogs; Electrocardiography; Infusions, Intravenous; Male; Pericarditis; Sotalol; Sulfonamides; Tachycardia, Atrioventricular Nodal Reentry | 1996 |
Redefining the role of antiarrhythmic drugs.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Chemotherapy, Adjuvant; Defibrillators, Implantable; Electric Countershock; Humans; Premedication; Sotalol; Sulfonamides; Tachycardia | 1999 |
Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Function; Biphenyl Compounds; Cation Transport Proteins; Electrophysiology; Ether-A-Go-Go Potassium Channels; Heart Atria; Hydantoins; Imidazoles; Imidazolidines; Kv1.5 Potassium Channel; Male; Phenethylamines; Piperazines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Pyridines; Sotalol; Sulfonamides; Swine; Ventricular Function | 2002 |
Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Function; Atropine; Biphenyl Compounds; Chromans; Flecainide; Heart Atria; Hydantoins; Imidazoles; Imidazolidines; Male; Phenethylamines; Piperazines; Potassium Channel Blockers; Potassium Channels; Propafenone; Propanolamines; Sotalol; Sulfonamides; Swine; Ventricular Function | 2004 |
[Perspectives and limitations in the treatment of vagus-induced atrial fibrillation. Insights from cellular pharmacology].
Topics: Adult; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cells, Cultured; Culture Media; Heart Atria; Humans; Membrane Potentials; Phenethylamines; Potassium Channel Blockers; Rats; Sotalol; Sulfonamides; Time Factors; Vagus Nerve | 2004 |
Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Electric Countershock; Electrophysiology; Flecainide; Goats; Models, Animal; Random Allocation; Refractory Period, Electrophysiological; Sotalol; Sulfonamides; Treatment Failure; Ventricular Remodeling | 2005 |